A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

Early Phase 1

Recruiting

Conditions: Osteosarcoma
Soft Tissue Sarcoma
Sarcoma
Bone Tumor

Interventions: Drug: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

Registration Number: NCT06171282

Lead Sponsor: Shanghai Yunying Medical Technology

Brief Summary: 9 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced bone and soft tissue tumors.

Detailed Description: Not available

Recruitment & Eligibility

Status: RECRUITING

Sex: All

Target Recruitment: 9

Inclusion Criteria

Age 16 to 75 years, diagnosed with soft tissue sarcoma or bone neoplasms clearly by histology and/or cytology.
Failure of standard treatment or patient unwillingness to receive other antitumor therapy.
No absolute or relative centasis contraindiction.
Subjects with ECoG score of 0-2.
Expected survival of 3 months or more.
Have at least one measurable lesion (according to RECIST 1.1 criteria) that is amenable to intratumoral drug delivery.
Subjects must have appropriate organ function, and laboratory tests during the screening period must meet the following requirements: a) absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelets (PLT) ≥ 80 × 109/L, and hemoglobin (Hb) ≥ 85 g/L; b) serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5 times the upper limit of normal values; c) serum total bilirubin (TBIL) ≤ 2 times the upper limit of normal values; d) glutamic aminotransferase (ALT) and glutamic oxalacetic aminotransferase (AST) ≤ 2.5 times the upper limit of normal values; subjects with liver metastases do not exceed 5 times the upper limit of normal values; e) activated partial thromboplastin time (APTT), prothrombin time (PT) within 1.5 times the upper limit of normal values.
Any treatment for malignancy, including radiotherapy, chemotherapy and biological agents, must be discontinued 28 days prior to R130 treatment.
Eligible patients of childbearing potential must agree to use a reliable method of contraception (hormonal or barrier method or abstinence) with their partner for the duration of the trial and for at least 180 days after the last dose; female patients of childbearing potential must have a negative urine pregnancy test within 7 days prior to enrollment.
Subjects voluntarily sign an informed consent form and are in good compliance.

Exclusion Criteria

Have had any serious adverse reactions associated with immunotherapy and have not recovered to CTCAE 5.0 grade rating 0 or 1 level of toxicity after previous antineoplastic therapy.
Subjects with any severe and/or uncontrolled disease, including: a) poorly controlled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); b) suffering from class I or higher myocardial ischemia or myocardial infarction, arrhythmia (QTc ≥ 470 ms and ≥ grade 2 congestive heart failure (New York Heart Association (NYHA) classification); c) active or uncontrolled severe infection (≥ CTCAE grade 2 infection); d) Patients with previous organ transplantation, bone marrow transplantation (hematopoietic stem cell transplantation) and severe immune deficiency; e) Urine routine suggesting urine protein ≥++ and confirmed 24-hour urine protein quantification > 1.0 g.
Patients with past history of type I diabetes mellitus or HIV.
Severe abnormalities in thyroid and cortisol testing; active, known or suspected autoimmune disease requiring systemic therapy.
Patients with active tuberculosis and a strong positive OT test.
Patients with active bleeding or severe coagulation dysfunction.
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Current active hepatitis B, active hepatitis C, immunodeficiency virus or other active infection of clinical significance.
Patients who have undergone surgery of grade 3 or higher or whose surgical wounds have not healed within 4 weeks prior to enrollment.
Pregnant, lactating and planning to have children within six months.
Subjects who, in the judgment of the investigator, are unsuitable for participation in this trial for any reason.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Experimental: R130 Treatment Group	Recombinant oncolytic herpes simplex virus type Ⅰ (R130)	Every 7-14 days,1-2 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral in patients with relapsed/refractory bone and soft tissue tumors.

Primary Outcome Measures

Name	Time	Method
Subject incidence of laboratory abnormalities	Up to 1 month	Detection of liver and renal function, electrocardiogram, routine blood examination etc
Subject incidence of adverse events	Up to 6 months	To characterize the safety profile of R130 injection in patients with relapsed/refractory bone and soft tissue tumors as measured by the incidence of Grade ≥ 3 Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0)
Systemic Immune Response	Up to 6 months	Detection of increased systemic immune Response markers in sera (IL2,IL4,IL6,IL8,IL10,TNFa，IFNγ, etc.) and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS)

Secondary Outcome Measures

Name	Time	Method
Quality of Life Assessment	Every 6 weeks for 12 months	Evaluate with EORTC QLQ-C30
Disease Assessment for Duration of Response	Every 10 weeks for 12 months	Evaluate the efficacy endpoints of DOR by the investigator with RECIST v1.1 and iRECIST
Disease Assessment for Disease Control Rate	Every 10 weeks for 12 months	Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST

Trial Locations

Locations (1): Shanghai General Hospital
🇨🇳
ShangHai, China